TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32572154

Group type: EXPERIMENTAL
Intervention: Remote digital pathology system from a non-CLIA certified facility
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Remote digital pathology system
Number of subjects: 12
Study: 35286526

Group type: EXPERIMENTAL
Intervention: 5 Hz rTMS over left dorsolateral prefrontal cortex (DLPFC) for 20 min
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham treatment over left dorsolateral prefrontal cortex (DLPFC) for 20 min
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 5 Hz rTMS
Number of subjects: 32
Study: 36040972

Group type: EXPERIMENTAL
Intervention: H7 coil
Number of subjects: 8

Group type: COMPARATOR
Intervention: D‐B80 coil
Number of subjects: 8
Study: 33947259

Group type: EXPERIMENTAL
Intervention: Subtotal intracapsular tonsillectomy (n=87)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Tonsillectomy (n=75)
Number of subjects: 162
Study: 36271950

Group type: EXPERIMENTAL
Intervention: 200-mg ibuprofen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 600-mg ibuprofen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 34853302

Group type: EXPERIMENTAL
Intervention: Intermittent vemurafenib (BRAFi) plus cobimetinib (MEKi)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard continuous vemurafenib (BRAFi) plus cobimetinib (MEKi)
Number of subjects: 0
Study: 36071224

Group type: EXPERIMENTAL
Intervention: Genomic analyses to target therapy
Number of subjects: 0
Study: 32192658

Group type: EXPERIMENTAL
Intervention: Contrast-associated acute kidney injury (CA-AKI)
Number of subjects: 4418

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned)
Number of subjects: 4418
Study: 33215762

Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Nilotinib 150 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Late-start nilotinib 150 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Nilotinib 150 mg vs 300 mg
Number of subjects: 63
Study: 35106880

Group type: EXPERIMENTAL
Intervention: 26 μg LSD
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 13 μg LSD
Number of subjects: 56
Study: 33009186

Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Controlled ventilation (bag-mask ventilation)
Number of subjects: 60
Study: 35689598

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB)
Number of subjects: 106
Study: 33745099

Group type: EXPERIMENTAL
Intervention: Relationship education and HIV prevention program for male couples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis (PrEP)
Number of subjects: 0
Study: 32220245

Group type: EXPERIMENTAL
Intervention: Intervention group (WHO food safety manual)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study: 34446223

Group type: EXPERIMENTAL
Intervention: Enhanced postoperative surveillance intervention
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Surgical staff enthusiasm for the trial
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Nursing management support of the trial
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Performance of a dummy run
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Nursing colleagues seeing the value of the intervention(s)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Site investigators' belief in the effectiveness of the intervention
Number of subjects: 96
Study: 32476009

Group type: EXPERIMENTAL
Intervention: SALAS score (5-25 points) assigned by trained reviewers based on video and voice recordings
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SALAS score
Number of subjects: 20
Study: 33624337

Group type: EXPERIMENTAL
Intervention: Mobile Gynaecological Cancer Support (MGCS) program for 24 weeks along with routine care
Number of subjects: 168

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 168
Study: 32986363

Group type: EXPERIMENTAL
Intervention: Cervical cancer treatment modalities (radiotherapy, brachytherapy, chemotherapy, surgery)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Out-of-pocket expenditure (OOPE)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Catastrophic health expenditure (CHE)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Distress financing
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Factors associated with CHE
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Factors associated with distress financing
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Health benefit package (HBP) cost for brachytherapy and radiotherapy
Number of subjects: 248
Study: 34096954

Group type: EXPERIMENTAL
Intervention: High protein product
Number of subjects: 34

Group type: COMPARATOR
Intervention: High carbohydrate (CHO) product
Number of subjects: 34

Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 34
Study: 33971853

Group type: EXPERIMENTAL
Intervention: Risk-predicted nomogram for sepsis associated-acute kidney injury (SA-AKI) developed through multivariate logistic regression analysis.
Number of subjects: 2871

Group type: EXPERIMENTAL
Intervention: Application of the nomogram in the validation cohort.
Number of subjects: 2871

Group type: EXPERIMENTAL
Intervention: Decision curve analysis (DCA) of the nomogram.
Number of subjects: 2871
Study: 32036491

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg daily on days 2-4)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (standard triplet regimen comprising aprepitant, a 5-HT3 receptor antagonist, and dexamethasone 7.5 mg on days 2-4)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study: 34775517

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Diode laser (980 nm, 3-W)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (1064, 1.0-W)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nanobioglass
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nanobioglass + diode laser (980 nm)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nanobioglass + Nd:YAG laser
Number of subjects: 36
Study: 34204618

Group type: EXPERIMENTAL
Intervention: High-polyphenolic nutraceutical
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 33374524

Group type: EXPERIMENTAL
Intervention: Encapsulated dry maté extract providing 580 mg of caffeoyl quinic acid derivatives (CQAs) daily
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Encapsulated dry maté extract
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Maté extract (subgroup analysis)
Number of subjects: 34
Study: 35857574

Group type: EXPERIMENTAL
Intervention: Women's Postpartum Sexual Health Program (WPSHP)
Number of subjects: 80
Study: 33876556

Group type: EXPERIMENTAL
Intervention: Combined hormonal contraceptives (CHCs)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no hormonal contraceptives)
Number of subjects: 16
Study: 32740481

Group type: EXPERIMENTAL
Intervention: E2/P4 1/100
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: E2/P4 0.5/100
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: E2/P4 0.5/50
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: E2/P4 0.25/50
Number of subjects: 726

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: E2/P4 (all doses)
Number of subjects: 726
Study: 33852195

Group type: EXPERIMENTAL
Intervention: Ketone ester (KE) ingestion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isocaloric glucose (GLU) administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo vehicle (PBO)
Number of subjects: 10
Study: 33856589

Group type: EXPERIMENTAL
Intervention: Resective surgery with the insertion of HAM patch (Group A)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Resective surgery (Group B)
Number of subjects: 49
Study: 35314922

Group type: EXPERIMENTAL
Intervention: New suturing technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine simple interrupted stitches (Control)
Number of subjects: 20
Study: 34520468

Group type: EXPERIMENTAL
Intervention: Availability intervention (replacing higher energy products with lower energy products)
Number of subjects: 20327

Group type: EXPERIMENTAL
Intervention: Availability plus size intervention (reducing portion size of higher energy products)
Number of subjects: 20327

Group type: EXPERIMENTAL
Intervention: Availability plus size intervention
Number of subjects: 20327
Study: 35365582

Group type: EXPERIMENTAL
Intervention: tofacitinib in the Oral Psoriatic Arthritis TriaL program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ixekizumab in the SPIRIT-P1 randomized controlled trial
Number of subjects: 0
Study: 32530321

Group type: EXPERIMENTAL
Intervention: Minimally invasive (MI) bilateral laminotomy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Open laminectomy
Number of subjects: 62
Study: 32560674

Group type: EXPERIMENTAL
Intervention: Mulch with nitrogen fertilizer application
Number of subjects: 4

Group type: COMPARATOR
Intervention: No mulch with nitrogen fertilizer application
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: High planting density with mulch and moderate N fertilizer application rate
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Different plant organs (leaf, grain, stem, cob)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Leaves
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Vegetative organ N translocation efficiency
Number of subjects: 4
Study: 35891905

Group type: EXPERIMENTAL
Intervention: White noise at 50 dB
Number of subjects: 66

Group type: COMPARATOR
Intervention: 0 dB (control group)
Number of subjects: 66
Study: 36116927

Group type: EXPERIMENTAL
Intervention: Recombinant poly-epitope vaccine EgG1Y162-2 (4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant multiepitope protein HIS-EgG1Y162-2 (4)
Number of subjects: 0
Study: 32172239

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35878952

Group type: EXPERIMENTAL
Intervention: 1-day practice group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-day practice group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-task condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-task condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirror test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-mirror test
Number of subjects: 0
Study: 34283844

Group type: EXPERIMENTAL
Intervention: Salt substitute
Number of subjects: 516

Group type: COMPARATOR
Intervention: Control
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Media intervention
Number of subjects: 516
Study: 32489777

Group type: EXPERIMENTAL
Intervention: Endeavor®-zotarolimus-eluting stent (E-ZES)
Number of subjects: 767

Group type: COMPARATOR
Intervention: Resolute integrity®-zotarolimus-eluting stent (I-ZES)
Number of subjects: 767
Study: 34156639

Group type: EXPERIMENTAL
Intervention: Basal diet with 50 mg/kg zinc acetate (T1)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Basal diet with 200 mg/kg zinc acetate (T2)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Basal diet with 300 mg/kg zinc acetate (T3)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Basal diet with normal zinc level (Control)
Number of subjects: 180
Study: 34807723

Group type: EXPERIMENTAL
Intervention: Routine fluid administration deemed inappropriate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-PCI interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right heart catheterization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left ventricular unloading strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Markers of futility for mechanical circulatory support escalation
Number of subjects: 0
Study: 35494511

Group type: EXPERIMENTAL
Intervention: Omaha system nursing (intervention group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Routine nursing (control group)
Number of subjects: 62
Study: 32459282

Group type: EXPERIMENTAL
Intervention: Resistant starch (RS) supplementation (16 g/day for four weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (manioc flour)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Resistant starch (RS) supplementation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Baseline measurements
Number of subjects: 42
Study: 35711677

Group type: EXPERIMENTAL
Intervention: Community-based dementia caregiver intervention (CDCI)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 78
Study: 34452904

Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 555

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study: 36008082

Group type: EXPERIMENTAL
Intervention: Ductal lavage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral corticosteroids (Methylprednisolone)
Number of subjects: 0
Study: 33927790

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine only
Number of subjects: 60
Study: 32758282

Group type: EXPERIMENTAL
Intervention: Propolis tablet (450 mg, containing 100 mg polyphenol compounds), twice daily for 6 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Identical placebo, twice daily for 6 weeks
Number of subjects: 52
Study: 35367091

Group type: EXPERIMENTAL
Intervention: Gastric aspiration after bimaxillary orthognathic surgery
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no gastric aspiration)
Number of subjects: 83
Study: 34487871

Group type: EXPERIMENTAL
Intervention: Ablative fractional laser-assisted photodynamic therapy (AFL-PDT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ablative fractional laser (AFL)
Number of subjects: 48
Study: 36056729

Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg
Number of subjects: 984

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study: 33819472

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (540,000 International Units)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 34969526

Group type: EXPERIMENTAL
Intervention: Training with real-time computer navigation feedback
Number of subjects: 20

Group type: COMPARATOR
Intervention: Simulation training without navigation feedback
Number of subjects: 20
Study: 32729954

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Adjacent untreated sites with recession at baseline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All sites (including ADM-treated and untreated)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Baseline KTW ≥2 mm
Number of subjects: 12
Study: 34688699

Group type: EXPERIMENTAL
Intervention: Teprotumumab treatment (8 infusions over 24 weeks)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Teprotumumab re-treatment
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Teprotumumab treatment
Number of subjects: 51
Study: 32663140

Group type: EXPERIMENTAL
Intervention: Interaktor app for symptom self-management
Number of subjects: 149
Study: 34315476

Group type: EXPERIMENTAL
Intervention: Attendance of at least four antenatal clinic visits (ANC 4+)
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding behavior
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: Regular attendance at community meetings
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: ANC 4+
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: Maternal age
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: Redistribution of exclusive breastfeeding behavior
Number of subjects: 3007
Study: 33027760

Group type: EXPERIMENTAL
Intervention: Plantar massage
Number of subjects: 0
Study: 33656986

Group type: EXPERIMENTAL
Intervention: Random projection strategy for nonparametric testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive testing procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upper bounds for tail sums of empirical kernel eigenvalues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulations and real data analysis
Number of subjects: 0
Study: 34277982

Group type: EXPERIMENTAL
Intervention: Hypoglycaemic clamp (2.2-2.5 mmol/L)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Euglycaemic clamp (4.5-5.5 mmol/L)
Number of subjects: 27
Study: 32158657

Group type: EXPERIMENTAL
Intervention: Microdebrider adenoidectomy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Coblation adenoidectomy
Number of subjects: 140
Study: 35538139

Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 59
Study: 32513143

Group type: EXPERIMENTAL
Intervention: Variable interval risk-based screening (6, 12, or 24 months)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Annual screening
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 6-month interval
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 12-month interval
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 2-year interval
Number of subjects: 51
Study: 35236764

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 3026

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 3026

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3026
Study: 32267951

Group type: EXPERIMENTAL
Intervention: EDOF Mini Well IOL
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mini‐4‐Ready IOL
Number of subjects: 50
Study: 32410519

Group type: EXPERIMENTAL
Intervention: Simple suction combined with pressure dressing (Group A)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Suction and local steroid injection (Group B)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Surgery (Group C)
Number of subjects: 84
Study: 32212778

Group type: EXPERIMENTAL
Intervention: Frequency of displacement after the disaster
Number of subjects: 345

Group type: COMPARATOR
Intervention: Control for age, gender, and traumatic exposure severity
Number of subjects: 345
Study: 35190345

Group type: EXPERIMENTAL
Intervention: Delirium prevention group (n = 284)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Standard care group (n = 274)
Number of subjects: 609
Study: 33216167

Group type: EXPERIMENTAL
Intervention: Nicotine (7 mg/24 h, transdermally)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mecamylamine (7.5 mg, p.o.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 18
Study: 32473556

Group type: EXPERIMENTAL
Intervention: Functional training with blood flow restriction (FTBFR)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Functional training (FT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study: 34902004

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - fluticasone propionate, 50 μg, with placebo, 2 puffs twice daily for 12 weeks
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids and long-acting β2 agonists (ICS/LABA) - fluticasone propionate, 50 μg, with salmeterol, 25 μg, 2 puffs twice daily for 12 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo inhalers
Number of subjects: 53
Study: 35524890

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention (8 sessions over 4 weeks)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control Group (Didactic health promotion group)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention
Number of subjects: 267
Study: 32361959

Group type: EXPERIMENTAL
Intervention: Underwater weight bath traction therapy and NSAIDs
Number of subjects: 176

Group type: COMPARATOR
Intervention: Weight bath
Number of subjects: 176

Group type: COMPARATOR
Intervention: Only NSAIDs
Number of subjects: 176
Study: 36191725

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 2900

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2900
Study: 33638928

Group type: EXPERIMENTAL
Intervention: Combination of Er: YAG laser and autologous platelet-rich plasma (PRP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Er: YAG laser
Number of subjects: 32
Study: 32847985

Group type: EXPERIMENTAL
Intervention: Durvalumab retreatment
Number of subjects: 70
Study: 35643769

Group type: EXPERIMENTAL
Intervention: HM3+VP
Number of subjects: 2200
Study: 33297866

Group type: EXPERIMENTAL
Intervention: Alteplase at 0.6 mg/kg intravenously
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 126
Study: 32317109

Group type: EXPERIMENTAL
Intervention: Myofascial release therapy (5 sessions over 2 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard physical therapy program (10 sessions of massage, ultrasound therapy, and transcutaneous electric nerve stimulation over 2 weeks)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Myofascial release therapy
Number of subjects: 54
Study: 36056444

Group type: EXPERIMENTAL
Intervention: TAVR-CMR protocol
Number of subjects: 250

Group type: COMPARATOR
Intervention: TAVR-CT protocol
Number of subjects: 250
Study: 35414801

Group type: EXPERIMENTAL
Intervention: Internet + hospital-to-home (H2H) model
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal nutritional nursing model (Control)
Number of subjects: 120
Study: 33974559

Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 223

Group type: COMPARATOR
Intervention: Normal control plasma
Number of subjects: 223
Study: 32321955

Group type: EXPERIMENTAL
Intervention: Self-assembling peptide P11-4 (SAP)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control teeth (no treatment)
Number of subjects: 23
Study: 35098880

Group type: EXPERIMENTAL
Intervention: Matching methods using real-world data (RWD) as control arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical control data
Number of subjects: 0
Study: 33592197

Group type: EXPERIMENTAL
Intervention: Self-management strategies (healthcare use, lifestyle changes, positive coping, avoidance)
Number of subjects: 267
Study: 36209050

Group type: EXPERIMENTAL
Intervention: Early child stimulation (categorized as low, moderate, and high stimulation based on PROCESS scores)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Early child stimulation (moderate to high quality)
Number of subjects: 516